Aegera Adds On

Aegera Therapeutics Inc., a Montreal-based drug developer, has acquired LymphoSign Inc., and its clinical oncology program that includes a tyrosine kinase inhibitor for acute myelogenous leukemia and other myelopproliferative disorders. No financial terms were disclosed. Aegera also raised a small amount of additional Series C equity funding